The European Medicines Agency (EMA) recently (31 March 2020) published its Regulatory Science Strategy to 2025.
The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines. The EMA said that the COVID-19 crisis only further underlines the need for greater cooperation and engagement between partners and stakeholders involved in the regulation of medicines and that key learnings from the current crisis would be incorporated into the strategy as data becomes available.
Safe, affordable medicines to meet patients needs
“The overall goal of the initiative is to help ensure Europe’s supply of safe and affordable medicines to meet patients’ needs and support the European pharmaceutical industry’s innovation efforts in the EU and globally,”
The five key goals of the strategy include:
catalysing the integration of science and technology in medicines development;
driving collaborative evidence generation - improving the scientific quality of evaluations;
advancing patient-centred access to medicines in partnership with healthcare systems;
addressing emerging health threats and availability/therapeutic challenges;
enabling and leveraging research and innovation in regulatory science.
For more information visit EMA website here.